Payment overview · 2025
General Payments
$273.06
15 reported records · 6 companies
Healthcare provider profile · identity verified
Joseph Robert Starke, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SAINT LOUIS, MO · NPI 1922414465
Verified facts
What the public records show
CMS Open Payments records show Joseph Robert Starke, D.O. received $273.06 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.40 | 29.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.13 | 24.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.30 | 21.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.10 | 15.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 6.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.28 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.21 | 14 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.13 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $66.13 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.30 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.74 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.10 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
54 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
101 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1149 | 280 |
| Levothyroxine Sodium | Levothyroxine Sodium | 704 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 690 | 171 |
| Lisinopril | Lisinopril | 607 | 176 |
| Gabapentin | Gabapentin | 594 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 474 | 122 |
| Furosemide | Furosemide | 449 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 393 | 46 |
| Omeprazole | Omeprazole | 393 | 109 |
| Losartan Potassium | Losartan Potassium | 385 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 67 |
| Eliquis | Apixaban | 354 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 352 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 349 | 74 |
| Metformin Hcl | Metformin Hcl | 332 | 92 |
| Metoprolol Tartrate | Metoprolol Tartrate | 332 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 93 |
| Carvedilol | Carvedilol | 267 | 57 |
| Montelukast Sodium | Montelukast Sodium | 263 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 246 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 101 |
| Trazodone Hcl | Trazodone Hcl | 222 | 55 |
| Sertraline Hcl | Sertraline Hcl | 203 | 46 |
| Alendronate Sodium | Alendronate Sodium | 197 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 195 | 30 |
| Mirtazapine | Mirtazapine | 190 | 22 |
| Potassium Chloride | Potassium Chloride | 188 | 46 |
| Tramadol Hcl | Tramadol Hcl | 187 | 26 |
| Xarelto | Rivaroxaban | 179 | 19 |
| Lorazepam | Lorazepam | 177 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 177 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 45 |
| Pregabalin | Pregabalin | 157 | 26 |
| Simvastatin | Simvastatin | 149 | 44 |
| Meloxicam | Meloxicam | 140 | 51 |
| Famotidine | Famotidine | 131 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 131 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 53 |
| Digoxin | Digoxin | 121 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 17 |
| Spironolactone | Spironolactone | 116 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | suppressed |
| Allopurinol | Allopurinol | 108 | 33 |
| Memantine Hcl | Memantine Hcl | 106 | 18 |
| Jardiance | Empagliflozin | 104 | 30 |
| Alprazolam | Alprazolam | 102 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 19 |
| Donepezil Hcl | Donepezil Hcl | 97 | 20 |
| Lovastatin | Lovastatin | 94 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 32 |
| Ezetimibe | Ezetimibe | 89 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 88 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 88 | suppressed |
| Clonazepam | Clonazepam | 86 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 85 | 15 |
| Buspirone Hcl | Buspirone Hcl | 85 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 84 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 29 |
| Levetiracetam | Levetiracetam | 80 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 65 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 48 |
| Fenofibrate | Fenofibrate Nanocrystallized | 74 | 19 |
| Topiramate | Topiramate | 74 | suppressed |
| Primidone | Primidone | 72 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 69 | 28 |
| Glipizide | Glipizide | 68 | 23 |
| Baclofen | Baclofen | 66 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 26 |
| Finasteride | Finasteride | 57 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 17 |
| Ozempic | Semaglutide | 56 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 54 | 54 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 22 |
| Bupropion Xl | Bupropion Hcl | 52 | 16 |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 15 |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | suppressed |
| Atenolol | Atenolol | 49 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 17 |
| Prednisone | Prednisone | 46 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Nystatin | Nystatin | 43 | 23 |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | 15 |
| Linzess | Linaclotide | 42 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 41 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 13 |
| Celecoxib | Celecoxib | 37 | 12 |
| Temazepam | Temazepam | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 20 |
| Doxepin Hcl | Doxepin Hcl | 32 | 13 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Valsartan | Valsartan | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 11 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 18 |
| Risperidone | Risperidone | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 17 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 17 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Ketoconazole | Ketoconazole | 21 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | 12 |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Propafenone Hcl | Propafenone Hcl | 21 | suppressed |
| Terconazole | Terconazole | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 13 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Nyamyc | Nystatin | 18 | 13 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Naproxen | Naproxen | 16 | 14 |
| Roflumilast | Roflumilast | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | 11 |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Fingolimod | Fingolimod Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.06 · 15 records | ABBVIE INC. | AREXVY, BEXSERO, JARDIANCE, OTEZLA, Ozempic, PENMENVY, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error